Amphastar Pharmaceuticals, Inc.

NasdaqGS:AMPH 주식 보고서

시가총액: US$1.9b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Amphastar Pharmaceuticals 미래 성장

Future 기준 확인 4/6

Amphastar Pharmaceuticals (는) 각각 연간 16.8% 및 12% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 16.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 25.7% 로 예상됩니다.

주요 정보

16.8%

수익 성장률

16.5%

EPS 성장률

Pharmaceuticals 수익 성장27.3%
매출 성장률12.0%
향후 자기자본 수익률25.7%
애널리스트 커버리지

Good

마지막 업데이트26 Jun 2024

최근 미래 성장 업데이트

Recent updates

Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming

Jul 01

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity

Amphastar Pharmaceuticals: Buy When Fear Is Overblown

May 30

Reassessing Amphastar Pharmaceuticals

May 15

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

May 13

I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

Apr 23
I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Feb 13
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

수익 및 매출 성장 예측

NasdaqGS:AMPH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20269372532302934
12/31/20258432162032395
12/31/20247521921482196
3/31/2024676155161198N/A
12/31/2023644138145184N/A
9/30/2023601135140175N/A
6/30/2023541102100131N/A
3/31/2023519935179N/A
12/31/2022499916589N/A
9/30/20224857790114N/A
6/30/2022477917097N/A
3/31/202245581100126N/A
12/31/2021438627198N/A
9/30/2021413364574N/A
6/30/2021384105281N/A
3/31/202136824579N/A
12/31/202035012357N/A
9/30/202033771346N/A
6/30/20203344-1125N/A
3/31/2020327521247N/A
12/31/201932249042N/A
9/30/201932952346N/A
6/30/2019324532773N/A
3/31/20193162-2326N/A
12/31/2018295-6-438N/A
9/30/2018265-7-538N/A
6/30/2018248-9-1525N/A
3/31/2018242-4-1025N/A
12/31/20172404N/A39N/A
9/30/20172430N/A43N/A
6/30/20172504N/A42N/A
3/31/20172529N/A47N/A
12/31/201625510N/A39N/A
9/30/201626921N/A28N/A
6/30/201626814N/A30N/A
3/31/20162540N/A23N/A
12/31/2015252-3N/A11N/A
9/30/2015230-13N/A20N/A
6/30/2015226-15N/A30N/A
3/31/2015221-10N/A28N/A
12/31/2014210-11N/A21N/A
9/30/2014209-6N/A17N/A
6/30/2014209-1N/A4N/A
3/31/20142238N/A24N/A
12/31/201323012N/A31N/A
9/30/201322714N/A35N/A

애널리스트 미래 성장 예측

수입 대 저축률: AMPH 의 연간 예상 수익 증가율( 16.8% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: AMPH 의 연간 수익( 16.8% ) US 시장( 14.9% 보다 빠르게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: AMPH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: AMPH 의 수익(연간 12% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: AMPH 의 수익(연간 12% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: AMPH 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 25.7 %)


성장 기업 발견